Lung Cancer Articles | Page 3

Frontline Alectinib Approved in Europe for ALK-Positive NSCLC
The European Commission has approved alectinib for the frontline treatment of patients with ALK-positive metastatic non–small cell lung cancer.
Immunotherapy and EGFR, ALK Inhibitors Deliver Precision Medicine in NSCLC
Edward S. Kim, MD, discusses the advancements in lung cancer in 2017, specifically in EGFR- and ALK-positive patients and those with PD-L1 expression.
Frontline Findings Put Fresh Focus on Immunotherapy in NSCLC
Findings from the phase III IMpower150 study have placed renewed focus on the optimal role for immunotherapy in the frontline setting for patients with advanced non
FDA Grants Frontline Osimertinib Priority Review for NSCLC
The FDA has granted a priority review to a supplemental new drug application for the use of osimertinib as a first-line treatment for patients with non–small cell lung cancer whose tumors harbor EGFR mutations.
Immunotherapy Emerges in Stage III NSCLC Treatment Landscape
John Heinzerling, MD, discusses the impact of durvalumab and other developments in the treatment of patients with stage III non-small cell lung cancer.
Deeper Understanding Emerging of KRAS Biology in NSCLC
Ferdinandos Skoulidis, MD, PhD, discusses potential treatment options for KRAS-mutated lung cancer and highlighted developments in biomarker research in other areas in the field.
Immunotherapy Resistance Remains a Puzzle
Checkpoint blockade immunotherapy has been hailed as a significant advance in anticancer treatment. Yet only a subset of patients experience long-term cancer remission as a result of these therapies, because a significant number of those who initially respond eventually develop resistance.
Treatment with the combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel delayed progression or death by 38% compared with bevacizumab and chemotherapy alone for patients with advanced non-squamous non–small cell lung cancer. 
Expert Discusses Developments in ALK/ROS1-Positive NSCLC
Vincent K. Lam, MD, discusses the treatment paradigm for patients with ALK/ROS1-translocated NSCLC.
Simon Says Immunotherapy Combo Regimens on Horizon in NSCLC
George R. Simon, MD, discusses the advancements being made with immunotherapy for the treatment of NSCLC.
Publication Bottom Border
Border Publication
x